Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 50 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Theodoros K.

Greece

USD 50 /hr

Pharmacology and Mass Spectrometry Expert | 10+ years of experience in preclinical drug development and LC-MS analysis

Profile Summary

Since the beginning of my PhD thesis in 2010, I have been working on research related with the development of targeted therapeutics. This training allowed me to build critical thinking towards drug development as well as a strong bioanalytical background that enabled the development of various challenging liquid chromatography-mass spectrometry (LC-MS) based assays and operating in a GLP environment. In addition, I have developed expertise regarding the different assays employed in all the stages of preclinical drug discovery in vitro and in vivo. Furthermore, I participated actively in the maintenance of an ISO17025 certification since 2010 and I have been involved in the organization of a Phase I clinical trials. The fact that I was in charge of the analysis of samples deriving from several clinical trials helped me built important experience regarding bioanalytical tasks that are governed by EMA/OECD guidelines such as bioanalytical method validation, analysis of samples and preparation of reports.

Subject Matter Expertise

• ☆ Bioinformatics
• ☆ Drug Development
• ☆ Medicine
• ☆ Technical & Scientific Writing
• ☆ Science Communication
• ☆ Scientific Proofreading & Editing

Services

• Writing
• Research
• Product Development

Writing Technical Writing, Copywriting

Research Fact Checking, Systematic Literature Review, Secondary Data Collection

Product Development Formulation

Work Experience

Postdoctoral Resarcher

BRFAA

June 2014 - Present

Education

PhD in Pharmacology

Biomedical Research Foundation of the Academy of Athens

October 2010 - June 2014

MSc in Industrial Biotechnology

Newcastle University upon Tyne

September 2004 - September 2005

BSc (Hons) in Biotechnology

Aberdeen University

September 1999 - July 2004

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Vrettos EI, Karampelas T, Sayyad N, Kougioumtzi A, Syed N, Crook T, Murphy C, Tamvakopoulos C, Tzakos AG(2020). Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer . European journal of medicinal chemistry.

Gavriil ES, Doukatas A, Karampelas T, Myrianthopoulos V, Dimitrakis S, Mikros E, Marakos P, Tamvakopoulos C, Pouli N(2019). Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy . European journal of medicinal chemistry.

Sayyad N, Vrettos EI, Karampelas T, Chatzigiannis CM, Spyridaki K, Liapakis G, Tamvakopoulos C, Tzakos AG(2019). Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile . European journal of medicinal chemistry.

Argyros O, Karampelas T, Varela A, Asvos X, Papakyriakou A, Agalou A, Beis D, Davos CH, Fokas D, Tamvakopoulos C(2017). Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule . Oncotarget.

Efthimiadou EK, Fragogeorgi E, Palamaris L, Karampelas T, Lelovas P, Loudos G, Tamvakopoulos C, Kostomitsopoulos N, Kordas G(2017). Versatile quarto stimuli nanostructure based on Trojan Horse approach for cancer therapy: Synthesis, characterization, in vitro and in vivo studies . Materials science & engineering. C, Materials for biological applications.

Spathis AD, Asvos X, Ziavra D, Karampelas T, Topouzis S, Cournia Z, Qing X, Alexakos P, Smits LM, Dalla C, et al.(2017). Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease . Proceedings of the National Academy of Sciences of the United States of America.

Karampelas T, Skavatsou E, Argyros O, Fokas D, Tamvakopoulos C(2017). Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy . Molecular pharmaceutics.

Malagari K, Kiakidis T, Pomoni M, Moschouris H, Emmanouil E, Spiridopoulos T, Sotirchos V, Tandeles S, Koundouras D, Kelekis A, et al.(2016). Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma . Cardiovascular and interventional radiology.

Argyros O, Karampelas T, Asvos X, Varela A, Sayyad N, Papakyriakou A, Davos CH, Tzakos AG, Fokas D, Tamvakopoulos C(2015). Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth . Cancer research.

Karampelas T, Argyros O, Sayyad N, Spyridaki K, Pappas C, Morgan K, Kolios G, Millar RP, Liapakis G, Tzakos AG, et al.(2014). GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery . Bioconjugate chemistry.

Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, Spyridopoulos T, Chatziioannou A, Sotirchos V, Karampelas T, et al.(2013). Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study . Cardiovascular and interventional radiology.